PDRN decreases the expression of cellular aging markers. by Jingjing Chen (293564)

Effects of GJE extract treatment decreased serum ALT and AST levels. by Natnicha Suttawong (22367172)

Effects of GJE extract treatment decreased accumulation of Col1a1. by Natnicha Suttawong (22367172)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

“…NF-κB p65 staining was higher in the NF group than controls (0.43 ± 0.11% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05) and decreased with low and high GJE doses (0.22 ± 0.04% and 0.29 ± 0.10%, respectively, <i><i>p</i> </i>< 0.05), though the high-dose group remained elevated versus controls (0.29 ± 0.10% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05). …”

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Estimated mean values for light interception. by Torsten Schober (20485754)

“…An increase in PD led to a linear decrease in inflorescence yield per plant (<i>p</i> = 0.02), whereas a positive linear relationship was found for inflorescence yield (<i>p</i> = 0.0001) and CBD yield (<i>p</i> = 0.0002) per m². …”

Effects of GJE extract treatment decreased protein expression of MMP-12, α-SMA, IL-13, and TGF-β1 levels. by Natnicha Suttawong (22367172)

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. by Guihua Wang (286390)

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Means scores of CAM and CAM-MYCS. by Senay Yildirim-Kahriman (22693464)

“…A moderate negative correlation was observed between CAM and CAM-MYCS scores (r = −0.511; p < 0.001), indicating that increased awareness of real causes is associated with decreased belief in myths. …”

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

“…Their median baseline variabilities of respiratory rate and tidal volume were 0.19 (IQR: 0.16–0.25) and 0.23 (0.19–0.34), respectively. While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …”

Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

The means pre-death food intake of all participants and each 4 groups for 24 weeks to death (Range 1-10). by Sakiko Fukui (387048)

Subjects:

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”